A New Drug Application (NDA) has been submitted to the Food and Drug Administration (FDA) for a transdermal patch formulation of asenapine for the treatment of schizophrenia. HP-3070 is being developed by Hisamitsu Pharmaceuticals in Japan in conjunction with its US subsidiary, Noven Pharmaceuticals. 

Results from a Phase 3 study evaluating the safety and efficacy of HP-3070 (N=617) showed that the treatment was associated with statistically significant improvement from baseline in the change of the total Positive and Negative Symptom Scale (PANSS) score at 6 weeks when compared with placebo. The most common adverse reactions associated with treatment included application site reaction, headache, and extrapyramidal disorder.

Related Articles

Asenapine is an atypical antipsychotic currently available as a sublingual tablet under the brand name Saphris (Allergan). 

For more information visit Noven.com.